842136-27-0

Basic information

• Product Name: 5-bromo-2,4-dimethylbenzoic acid
• Synonyms: 5-bromo-2,4-dimethylbenzoic acid
• CAS NO: 842136-27-0
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 842136-27-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2,4-dimethylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2,4-dimethylbenzoic acid(842136-27-0)
• EPA Substance Registry System: 5-bromo-2,4-dimethylbenzoic acid(842136-27-0)

Safety Data

• Hazardous Substances Data: 842136-27-0(Hazardous Substances Data)

Usage

Description

5-bromo-2,4-dimethylbenzoic acid is a benzoic acid derivative with the molecular formula C9H9BrO2. It features a benzoic acid ring with a bromine atom and two methyl groups attached, making it a valuable and versatile compound in organic chemistry.

Uses

Used in Organic Synthesis:
5-bromo-2,4-dimethylbenzoic acid is used as a building block for the synthesis of various organic compounds. Its unique structural characteristics allow it to be a key component in the creation of new molecules with potential applications in various industries.
Used in Pharmaceutical Research:
5-bromo-2,4-dimethylbenzoic acid is utilized as a starting material in the development of pharmaceuticals. Its potential applications in the creation of new drugs make it an important compound in the field of medicinal chemistry.
Used in Agrochemical Development:
5-bromo-2,4-dimethylbenzoic acid is also used in the development of agrochemicals. Its properties and reactivity make it a promising candidate for the synthesis of new agrochemicals with potential applications in agriculture.
Used as a Reagent in Chemical Reactions:
5-bromo-2,4-dimethylbenzoic acid serves as a reagent in various chemical reactions. Its ability to participate in different types of reactions makes it a useful tool in the synthesis of other compounds.
Used as a Reference Standard for Analytical Assays:
5-bromo-2,4-dimethylbenzoic acid is employed as a reference standard in analytical assays. Its well-defined structure and properties make it an ideal compound for calibration and quality control purposes in various analytical techniques.

Upstream product

• 2623-45-2 2-chloro-1-(2,4-dimethyl-phenyl)-ethanone 
• 5469-19-2 1-bromo-2,4,5-trimethylbenzene 
• 615-87-2 1,5-dibromo-2,4-dimethylbenzene 
• 383176-10-1 5-bromo-2,4-dimethylbenzaldehyde 
• 807628-76-8 5-bromo-2,4-dimethylbenzonitrile 
• 89-74-7 2,4-dimethylacetophenone. 
• 611-01-8 2,4-dimethyl-benzoic acid 
• 124-38-9 carbon dioxide 
• 7697-37-2 nitric acid 
• 95-63-6 1,2,4-Trimethylbenzene 
• 854693-48-4 5-bromo-2,4-dimethyl-benzyl chloride 
• 824-55-5 2,4-dimethyl-benzyl chloride 
• 152849-72-4 methyl 3-bromo-2,4-dimethylbenzoate 
• 110-05-4 di-tert-butyl peroxide 

Downstream Products

• 152849-72-4 methyl 3-bromo-2,4-dimethylbenzoate 
• 151859-36-8 C₇₀H₈₅BrO₃ 
• 159217-49-9 Bis-{5-[bis-(4-tert-butyl-phenyl)-methoxy-methyl]-2,4-dimethyl-phenyl}-(5-bromo-2,4-dimethyl-phenyl)-methanol 
• 1403595-71-0 5-bromo-2,4-dimethyl-3-nitrobenzoic acid 
• 1403595-72-1 methyl 5-bromo-2,4-dimethyl-3-nitrobenzoate 
• 1403595-73-2 methyl 3-amino-5-bromo-2,4-dimethylbenzoate 
• 1403595-74-3 methyl 5-bromo-3-(cyclopentylamino)-2,4-dimethylbenzoate 
• 1403595-75-4 methyl 5-bromo-3-(cyclopentyl(methyl)amino)-2,4-dimethylbenzoate 
• 1403595-76-5 C₁₅H₂₀BrNO₂ 

Relevant articles and documents

2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein α, β, R2, R3, R4, R5, R8, R9, X1, X6, and X7 are defined in the specification. The compounds of formula 1 are receptor-interacting protein kinase 2 (RIPK2) inhibitors for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 107 to 208; examples 1 to 109; table 1). An exemplary compound is e.g. N-cyclopropyl-2-fluoro-5-(l-(2-fluoroethyl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-oxo-2,3-dihydro-lH-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide (example 1).

Palladium-Catalyzed ortho-C-H Methylation of Benzoic Acids

A palladium-catalyzed methylation of C-H bonds of benzoic acids with di-tert-butyl peroxide as the methylating reagent under an external oxidant and ligand-free conditions has been achieved. The reaction is found to be directed by a weakly coordinating carboxyl group, offering a facile route for the synthesis of highly functionalized ortho-methyl benzoic acids.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.